Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-12
2006-09-12
Price, Elvis O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S045000, C514S042000, C514S050000, C514S052000, C514S046000, C536S028400, C536S028500, C536S026120
Reexamination Certificate
active
07105499
ABSTRACT:
The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside derivatives of the present invention.
REFERENCES:
patent: 3480613 (1969-11-01), Walton
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6784161 (2004-08-01), Ismaili et al.
patent: 2002/0019363 (2002-02-01), Ismaili et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0198171 (2002-12-01), Schinazi et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: 1.581.628 (1969-09-01), None
patent: 1209 654 (1970-10-01), None
patent: WO 93/18051 (1993-09-01), None
patent: WO 99/43691 (1999-09-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/79246 (2001-10-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/92282 (2001-12-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/048165 (2002-06-01), None
patent: WO 02/048165 (2002-06-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100354 (2002-12-01), None
patent: WO 02/100354 (2002-12-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/000200 (2003-01-01), None
patent: WO 03/000713 (2003-01-01), None
patent: WO 03/015798 (2003-02-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051881 (2003-06-01), None
patent: WO 03/051896 (2003-06-01), None
patent: WO 03/051897 (2003-06-01), None
patent: WO 03/051898 (2003-06-01), None
patent: WO 03/051899 (2003-06-01), None
patent: WO 03/062255 (2003-07-01), None
Walton, E. et al., “Branched-Chain Sugar Nucleosides. V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides”, J. Med. Chem., vol. 12, pp. 306-309 (1969).
Matsuda, A. et al., “Radical Deoxygenation of Tert-Alcohols In 2′-Branched-Chain Sugar Pyrimidine Nucleosides: Synthesis and Antileukemic Activity of 2′-Deoxy-2′ (S)-Methylcytidine”, Chem. Pharm. Bull., vol. 35, pp. 3967-3970 (1987).
Matsuda, A. et al., Alkyl Addition Reaction of Pyrimidine 2′-Ketonucleosides: Synthesis of 2′-Branched-Chain Sugar Pyrimidine Nucleosides (Nucleosides and Nucleotides. LXXXI). Chem. Pharm. Bull., vol. 36, pp. 945-953 (1988).
Murai, Y. et al., “A Synthesis and an X-Ray Analysis of 2′-C-, 3′-C- and 5′-C-Methylsangivamycins”, Heterocycles, vol. 33, pp. 391-404 (1992).
Limori, T. et al., “2′-C-, 3′-C- and 5′-C-Methylsangivamycins: Conformational Lock with the Methyl Group”, Tetrahedron Letters, vol. 3, No. 49, pp. 7273-7276 (1991).
Wolfe, M. et al., “A Consise Synthesis of 2′-C-Methylribonucleosides”, Tetrahedron Letters, vol. 36, No. 42, pp. 7611-7614 (1995).
Harry-O'kuru, R. et al., “A Short, Flexible Route toward 2′-C-Branched Ribonucleosides”, J. Org. Chem., vol. 62, pp. 1754-1759 (1997).
Gallo, M. et al., “Synthesis of 2′-Modified Nucleotides”, Molecules, vol. 5, pp. 727-729 (2000).
Beigelman, L. et al., “New Synthesis of 2′-C-Methylnucleosides Starting From D-Glucose and D-Ribose”, Carbohydrate Research, vol. 166, pp. 219-232 (1987).
Anzai, K. et al, “A New Antibiotic, Tubercidin”, The Journal of Antibiotics., vol. X, No. 5, pp. 201-205 (1957).
Tolman, R. et al., “Pyrrolopyrimidine Nucleosides. III. The Total Synthesis of Toyocamycin, Sangivamycin, Tubercidin, and Related Derivatives”, Journal of the American Chemical Society, vol. 91, No. 8, pp. 2102-2108 (1969).
Tolman, R. et al., “Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotics. Total Synthesis and Structure of Toyacamycin, Unamycin B, Vengicide, Antibiotic E-212, and Sangivamycin (BA-90212)”, Journal of the American Chemical Society, vol. 90, No. 2, pp. 24-526 (1968).
Siddiqi, S. et al., “Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors”, J. Med. Chem., vol. 38, pp. 1174-1188 (1995).
Franchetti, P. et al., “2′-Methyl Analogues of Selective Adenosine Receptor Agonists: Synthesis and Binding Studies”, J. Med. Chem., vol. 41, pp. 1708-1715 (1988).
Kalinichenko, E. et al., “Substrate Specificity of Adenosine Deminase. Role of Methyl Groups at the 2′-3′-, and 5′-Carbon Atoms of Adenosine”, Bioorganicheskaya Khimiya, vol. 14, No. 9, pp. 1157-1161 (1988).
Wolf, et al., “New 2′-C-Branched-Chain Sugar Nucleoside Analogs with Potential Antiviral or Antitumor Activity”, Synthesis, pp. 773-778 (Aug. 1992).
Bhat Balkrishen
Carroll Steven S.
Cook Phillip Dan
Eldrup Anne B.
MacCoss Malcolm
Durette Philippe L.
Henry Michael C.
Isis Pharmaceuticals , Inc.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Nucleoside derivatives as inhibitors of RNA-dependent RNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside derivatives as inhibitors of RNA-dependent RNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives as inhibitors of RNA-dependent RNA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561051